DECODE Biologic-Describing the Consequences of Delays in Biologic initiation Study
Enrolling By Invitation
18 years - 99 years
All
Phase
N/A
65 participants needed
1 Location
Brief description of study
This
study plans to learn more about the usage and effect of biologic medications
with patients that have inflammatory bowel disease (IBD). IBD includes both
Crohn’s Disease (CD) and Ulcerative Colitis (UC), which currently affects
around 1.5 million Americans. Medical therapies for IBD focus on reducing the
inflammation of the gastrointestinal tract to improve symptoms and begin
mucosal healing. Tumor Necrosis Factor-alpha (TNF) is a type of protein
that can increase inflammation. Higher amounts of TNF are found in people with
IBD. Biologic medications directed against Tumor Necrosis Factor-alpha
(Anti-TNFs) have been shown to target the TNFs to improve the course of IBD.
Subjects
will be consented and enrolled by Penn study staff either in-person through the
GI clinic or via telephone, using an IRB approved telephone script. Only
individuals greater than or equal to 18 years of age with a documented
diagnosis of Crohn’s Disease (CD) or Ulcerative Colitis (UC) who have initiated
new biologic therapy will be considered eligible for inclusion.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Inflammatory Bowel Disease,Crohs Disease,Ulcerative Colitis
-
Age: 18 years - 99 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 833081
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
